Flurandrenolide

Summary

Flurandrenolide (CHEMBL1201012) is an approved small molecule (ATC D07AC07); indicated across 2 conditions including skin disorder and chronic kidney disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D07AC07
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 436.5 Da · C24H33FO6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201012
Name	Flurandrenolide
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	15209
ATC	D07AC07
Molecular formula	C24H33FO6
Molecular weight	436.5
InChIKey	POPFMWWJOGLOIF-XWCQMRHXSA-N

SMILES: C[C@]12CCC(=O)C=C1[C@H](C[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CO)C)O)F

IUPAC name: (1S,2S,4R,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icos-17-en-16-one

Also known as: Cordran, Cordran sp, Fludroxicortida, Fludroxicortide, Fludroxycortide, Flurandrenolide, Flurandrenolide component of cordran-n, Flurandrenolone, Haelan, Haelan-c, Haelan-x, NSC-757869

Patent coverage: 4,638 distinct patent families (18,066 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 10 (assay-derived). Sample: Nuclear receptor ROR-gamma, Survival motor neuron protein, Ferritin light chain, Androgen receptor, Beta-lactamase, Glucocorticoid receptor, Progesterone receptor, Hypoxia-inducible factor 1-alpha, Neuropeptide S receptor, Bile salt export pump.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 12 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NR3C1	8.69	Ki	2.02	nM	CHEMBL_ACT_7672210
NR3C1	8.35	IC50	4.45	nM	CHEMBL_ACT_7672209
HIF1A	8.2	Potency	6.3	nM	CHEMBL_ACT_4125766
HIF1A	8.2	Potency	6.3	nM	CHEMBL_ACT_4519975
PGR	7.18	AC50	66.6	nM	CHEMBL_ACT_25204021
NPSR1	6.5	Potency	316.2	nM	CHEMBL_ACT_4929132
SMN1	6.05	Potency	891.3	nM	CHEMBL_ACT_3888883

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
skin disorder	4	MONDO:0005093	EFO:0000701
chronic kidney disease	3	MONDO:0005300	MONDO:0024327

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00558558	PHASE2	TERMINATED	Haelan and Nutrition in Cancer Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).